The document is an intimation regarding the availability of an audio recording for a conference call discussing financial results.
The conference call was held on 28th October 2026 (specific time not mentioned in the document).
The purpose of the call was to discuss the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.
The call occurred after the earnings announcement, as it references a previous letter dated 16th October 2026.
No specific management participants or their designations were mentioned in this disclosure.
The audio recording of the conference call has been made available on the Company's website at https://www.piramalpharma.com/financialreports.
The document does not contain any statement regarding whether unpublished price sensitive information (UPSI) was or was not shared during the call.
Financial Information
No financial highlights, guidance references, or presentation summaries were included in this specific disclosure document.
The financial period discussed in the referenced call was the quarter and half year ended 30th September, 2026.
Additional Notes Section
This is a standalone regulatory filing without any mentioned attachments such as invites, investor decks, or compliance letters.
No financial data or figures were disclosed in this announcement letter.
The disclosure was made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The letter was digitally signed by Maneesh Sharma, Company Secretary & Compliance Officer, on 28th October 2026 at 14:56:32 IST.
